Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Absci Corporation - Common Stock (NQ:ABSI)

3.638 -0.022 (-0.60%)
Streaming Delayed Price Updated: 10:33 AM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Absci Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI
The collaboration unites Absci’s Generative AI Drug Creation Platform with leading oncology experts to co-develop up to six novel cancer therapeutics 
From Absci Corporation
Via GlobeNewswire
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
The Analyst Verdict: Absci In The Eyes Of 6 Experts
 
Via Benzinga
6 Analysts Assess Absci: What You Need To Know
 
Via Benzinga
Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024
From Absci Corporation
Via GlobeNewswire
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Absci Corporation
Via GlobeNewswire
Clinical-Stage BioTech Drug Stocks Declined 13% In June
Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read 
Via Talk Markets
Cathie Wood's Ark Invest Sells Coinbase Shares As Bitcoin Drops Below Key $62K Level
On Monday, Cathie Wood-led Ark Invest made some significant trades, with Coinbase Global Inc. (NASDAQ:COIN) taking the spotlight. This comes amidst a turbulent market scenario, particularly for... 
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
From Absci Corporation
Via GlobeNewswire
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
The global 
Via Talk Markets
Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moderna Inc (NASDAQ:MRNA), Palantir 
Via Benzinga
Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Absci Corporation
Via GlobeNewswire
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process... 
Via Talk Markets
Topics Artificial Intelligence
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q1 2024
ABSI stock results show that Absci missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
Via Talk Markets
All 7 AI Category Portfolios Continued To Decline This Week
All 54 AI stocks in the 7 AI category portfolios dropped this week, down 8.4%, on average, making it clear that the surge in the AI sector that began back on October 31st is over. 
Via Talk Markets
Topics Artificial Intelligence
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
From Absci Corporation
Via GlobeNewswire
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during Tuesday’s session. 
Via Benzinga
Topics Stocks
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Absci Corporation
Via GlobeNewswire
ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q4 2023
ABSI stock results show that Absci missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.